Effects of montelukast in an experimental model of acute pancreatitis

ArticleAçık Erişim

Özet

Background: We evaluated the hematological, biochemical, and histopathological effects of Montelukast on pancreatic damage in an experimental acute pancreatitis model created by cerulein in rats before and after the induction of pancreatitis. Materials/Methods: Forty rats were divided into 4 groups with 10 rats each. The study groups were: the Cerulein (C) group, the Cerulein + early Montelukast (CMe) group, the Cerulein + late Montelukast (CMl) group, and the Control group. The pH, pO2, pCO2, HCO3, leukocyte, hematocrit, pancreatic amylase, and lipase values were measured in the arterial blood samples taken immediately before rats were killed. Results: There were statistically significant differences between the C group and the Control group in the values of pancreatic amylase, lipase, blood leukocyte, hematocrit, pH, pO2, pCO2, HCO3, and pancreatic water content, and also in each of the values of edema, inflammation, vacuolization, necrosis, and total histopathological score (P<0.05). When the CMl group and C group were compared, no statistically significant differences were found in any parameter analyzed. When the CMe group was compared with the C group, pancreatic amylase, lipase, pH, PO2, pCO2, HCO3, pancreatic water content, histopathological edema, inflammation, and total histopathological score values were significantly different between the groups (P<0.05). Finally, when the CMe group and the Control group were compared, significant differences were found in all except 2 (leukocyte and pO2) parameters (P<0.05). Conclusions: Leukotriene receptor antagonists used in the late phases of pancreatitis might not result in any benefit; however, when they are given in the early phases or prophylactically, they may decrease pancreatic damage. © Med Sci Monit.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/14516Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.12659/msm.896919Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorAngı, Serkan
dc.contributor.authorEken, Hüseyin
dc.contributor.authorKılıç, Erol
dc.contributor.authorKaraköse, Oktay
dc.contributor.authorBalci, Gürhan
dc.contributor.authorSomuncu, Erkan
dc.date.accessioned2026-10-18T20:29:19.688427660Z
dc.date.available2026-10-18T20:29:19.688427660Z
dc.date.issued2016
dc.description.abstractBackground: We evaluated the hematological, biochemical, and histopathological effects of Montelukast on pancreatic damage in an experimental acute pancreatitis model created by cerulein in rats before and after the induction of pancreatitis. Materials/Methods: Forty rats were divided into 4 groups with 10 rats each. The study groups were: the Cerulein (C) group, the Cerulein + early Montelukast (CMe) group, the Cerulein + late Montelukast (CMl) group, and the Control group. The pH, pO2, pCO2, HCO3, leukocyte, hematocrit, pancreatic amylase, and lipase values were measured in the arterial blood samples taken immediately before rats were killed. Results: There were statistically significant differences between the C group and the Control group in the values of pancreatic amylase, lipase, blood leukocyte, hematocrit, pH, pO2, pCO2, HCO3, and pancreatic water content, and also in each of the values of edema, inflammation, vacuolization, necrosis, and total histopathological score (P<0.05). When the CMl group and C group were compared, no statistically significant differences were found in any parameter analyzed. When the CMe group was compared with the C group, pancreatic amylase, lipase, pH, PO2, pCO2, HCO3, pancreatic water content, histopathological edema, inflammation, and total histopathological score values were significantly different between the groups (P<0.05). Finally, when the CMe group and the Control group were compared, significant differences were found in all except 2 (leukocyte and pO2) parameters (P<0.05). Conclusions: Leukotriene receptor antagonists used in the late phases of pancreatitis might not result in any benefit; however, when they are given in the early phases or prophylactically, they may decrease pancreatic damage. © Med Sci Monit.
dc.identifier.doi10.12659/msm.896919
dc.identifier.endpage2719
dc.identifier.issn1234-1010
dc.identifier.pmcidPMC4972074
dc.identifier.pmid27479458
dc.identifier.scopus2-s2.0-84983460515
dc.identifier.startpage2714
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/14516
dc.identifier.volume22
dc.identifier.wosWOS:000381308200002
dc.language.isoen
dc.publisherInternational Scientific Literature Inc.
dc.relation.ispartofMedical Science Monitor
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcute necrotizing
dc.subjectCerulenin
dc.subjectMontenegro
dc.subjectPancreatitis
dc.subjectAcetates
dc.subjectAmylases
dc.subjectAnimals
dc.subjectCeruletide
dc.subjectDisease Models, Animal
dc.subjectEdema
dc.subjectLeukotriene Antagonists
dc.subjectLipase
dc.subjectMale
dc.subjectQuinolines
dc.subjectRats
dc.subjectRats, Sprague-Dawley
dc.subjectalpha amylase pancreas isoenzyme
dc.subjectbicarbonate
dc.subjectmontelukast
dc.subjecttriacylglycerol lipase
dc.subjectacetic acid derivative
dc.subjectamylase
dc.subjectleukotriene receptor blocking agent
dc.subjectquinoline derivative
dc.subjectacute pancreatitis
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectblood gas analysis
dc.titleEffects of montelukast in an experimental model of acute pancreatitis
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus2
rdl.citation.wos1
rdl.departmentDepartment of Pathology, Erzincan University, Erzincan, Turkey. | Department of General Surgery, Erzincan University, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)